Revive Therapeutics To Investigate Novel Oral Dosage Forms Of Psilocybin

Revive Therapeutics (CSE: RVV) has provided an update to the market in regards to its psilocybin-based pharmaceutical program. Revive intends to utilize its patent-pending psilocybin formulations and its exclusive licensed drug delivery technology to investigate novel oral dosage forms of psilocybin, such as in the form of tablets or thin films like breath strips.

It has been found that several parallels exists between Revive’s IP portfolio of psilocybin-based formulations and that of the composites the firm studied with cannabidiol in the past when it comes to drug delivery mechanisms. As a result, Revive intends to research both methods together, as both provide unique qualities such as the potential for time release compositions and rapid on-set. To this end, Revive believes the most ideal delivery method will be that of an oral dissolvable tablet or an oral film strip, commonly referred to as a breath strip.

The firms psilocybin-based formulations have been created to synergistically work with the natural pathways of absorption found in the body. The current formulation development plans intend to pursue clinical studies for indications not currently being evaluated with psilocybin, while using the firms unique delivery platform IP as an advantage. For this, Revive will lean on its patent-pending technology that covers methods of producing psilocybin formulations as well as its extraction and crystallization methodologies.

"We are expanding our psilocybin-based pharmaceutical portfolio with unique oral dosage and drug delivery forms that will target and have the potential to treat diseases and disorders currently not investigated with psychedelic compounds. We are combining our robust intellectual property portfolio in both psychedelic formulations and our drug delivery technology which is unique within the industry, and leveraging our research partnership with the University of Wisconsin-Madison to establish a specialty portfolio of psilocybin-based pharmaceuticals that we can advance to clinical trials and partnerships with other life sciences companies." Michael Frank, CEO

Revive Therapeutics last traded at $0.14 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

Is Gold’s Bull Market About to Hit Junior Stocks? | Ken Armstrong – Westhaven Gold

Surge Battery Metals: The Nevada North Lithium PEA

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Revive Therapeutics Selects Novotech As APAC Contract Research Organization

Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a...

Wednesday, April 8, 2020, 09:37:45 AM

Revive Therapeutics Provides Market Update On Cannabinoid Related Research

Revive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid...

Thursday, February 11, 2021, 08:01:25 AM

Revive Therapeutics Director Signs Manufacturing Arrangement With Vaxart

It appears that Revive Therapeutics (CSE: RVV) has a budding superstar on its board of...

Thursday, July 2, 2020, 10:16:41 AM

Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics

Bucillamine Just Got Cleared for Phase 3 Trials of COVID-19 On Friday, July 31, 2020...

Monday, August 3, 2020, 10:11:55 AM

Revive Therapeutics Doubles Bought Deal Financing To $20.0 Million

Revive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged...

Thursday, January 21, 2021, 10:04:38 AM